Avanos Medical (AVNS)
(Delayed Data from NYSE)
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 6:46 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 6:46 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
Zacks News
Why Is Avanos Medical (AVNS) Up 5.7% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter results benefit from contribution from Chronic Care segment.
Avanos Medical (AVNS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 262.50% and 10.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Avanos Medical (AVNS) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, stiff competition remains a concern.
Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter results benefit from segmental contribution.
Avanos Medical (AVNS) Lags Q1 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -5.88% and 4.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Avanos Medical Stock Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, weak performance at Acute Pain unit raises concern.
Why Is Avanos Medical (AVNS) Down 30.2% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Avanos Medical (AVNS) Stock Now
by Zacks Equity Research
Avanos (AVNS) gains from solid fourth-quarter show despite headwinds in the Acute Pain business.
Avanos (AVNS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Avanos (AVNS) gains from segmental contributions in Q4.
Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 6.25% and 6.73%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for January 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Why Is Avanos Medical (AVNS) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.
Avanos Medical (AVNS) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -6.25% and -5.11%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Avanos Medical (AVNS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) Catches Eye: Stock Jumps 6.2%
by Zacks Equity Research
Avanos Medical (AVNS) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
AngioDynamics Boosts VIT Product Portfolio With New Buyout
by Zacks Equity Research
AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.
Avanos Medical (AVNS) Down 8.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for August 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today